Accès ouvert
2026
article
OpenAlex
John Hixson, Jerry Shih, Sharona Ben‐Haim, Robert Beach et autres
Neurona Therapeutics is investigating NRTX-1001 cell therapy in two open-label, multicenter Phase 1/2 trials for drug-resistant unilateral (NCT05135091) and bilateral (NCT06422923) mesial temporal lobe epilepsy (MTLE). GABAergic cortical interneurons from the medial ganglionic eminence (MGE) are promising therapeutic targets in developing novel …
us
(code pays fourni par la source)
2026
article
OpenAlex
Peter Warnke, Naoum P. Issa, Kevin Graber, Vivek Buch et autres
To present results from an ongoing open-label, multicenter Phase 1/2 trial (NCT06422923) evaluating NRTX-1001 cell therapy for the treatment of seizures due to bilateral drug-resistant mesial temporal lobe epilepsy (MTLE).
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Utku Uysal, Patrick Landazuri, David E. Burdette, Sanjay Patra et autres
OBJECTIVE: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures (GTCSs). METHODS: NAUTILUS is a prospective, multicenter, single-blind, randomized sham-controlled pivotal trial. Patients were …
us
(code pays fourni par la source)